Aatru Medical Abstract Accepted for Presentation in Two Leading 2020 Wound Healing Conferences
Innovative Negative Pressure Wound Therapy for Surgical Incisions
Cleveland -- Aatru Medical, LLC ('Aatru') announced today that its technical Abstract has been accepted for presentation at both the SAWC/WHS 2020 conference in North Carolina and also at EWMA 2020, to be held in London, England. The 2020 Symposium on Advanced Wound Care (SAWC)/Wound Healing Society (WHS) meeting is the largest gathering of wound care professionals in the US. The European Wound Management Association’s (EWMA) 30th annual conference will take place in November. Both events feature lectures, sessions, and symposiums that focus on all aspects of wound care and management.
The pre-clinical research Abstract is entitled, “A pilot study on closed porcine incisions of a novel low-cost, solid-state NPWT device.” The Abstract was authored by Stephen Davis and his team at University of Miami Miller School of Medicine, Department of Dermatology & Cutaneous Surgery, with assistance from Robin Martin PhD Scientific Consulting.
The Abstract describes the 7-day porcine study, the methods of surgery and data gathering, and the results over a seven-day test period. This pilot study tested Aatru Medical’s NPSIMSTM technology (Negative Pressure Surgical Incision Management System), a patented, low-cost-ofmanufacture, non-electrical device that uses solid state oxygen management technology (OxMT) to create and sustain a mean negative pressure of -81.1 mmHg in test negative pressure wound therapy (NPWT) dressings. In addition to demonstrating comparable therapy to an existing electrical NPWT device, this pilot study provided indications that the OxMT technology of Aatru’s NPSIMSTM product may have a beneficial effect on limiting bacterial viability in the wound.
Dr. Robin Martin, who participated in the study and Abstract and who will also provide the video presentation at EWMA, noted, “It has been fascinating to work with this ingenious technology which uses the relative abundance of oxygen in the atmosphere to apply and maintain therapeutic NPWT without any electronic components.”
Aatru Medical Chief Technology Officer, John Buan, PhD who also assisted in the design and preparation of the study commented, “This small pilot study demonstrates the potential for Aatru’s revolutionary OxMT technology to reset the bar for surgical incision NPWT devices in the areas of cost-benefit and clinical ease-of-use.”
A copy of the Abstracts can be found on the Aatru Medical company website at www.aatru.com. Aatru is a privately held medical device technology company focused on disrupting the surgical incision market with its NPSIMS, a simple, disposable, single-use, patented, low-cost NPWT device, uniquely designed to require no electromechanical pump, battery or canister.
Related products
Related services
Related news
-
Anuncia Medical Announces the First Successful US Implant of the Company’s Newly Commercially Released ReFlow Mini Flusher Device for Hydrocephalus Patients
Intermountain Primary Children’s Hospital First in the Country to Implant this Next Generation FDA-Cleared Device Company Welcomes Vice President of Sales & Marketing, Mark Geiger, Who Lives with Hydrocephalus Anuncia Medical Inc. (“Anuncia” or the “Company”), a Company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce the successful first implant of the Company’s...
-
7-year-old Boy Managing His Hydrocephalus with ReFlow Ventricular System “Gen 1” Featured on Charleston’s ABC News 4
After struggling to conceive a child for what felt like ages, Miranda of Moncks County, South Carolina finally fell pregnant - a miracle that quickly turned into horror when she delivered at 24 weeks in late 2015. At just 1 pound and 12 ounces, her son, Sutton, arrived with life-threatening health issues, including hydrocephalus - a neurological disorder caused by an abnormal buildup of cerebrospinal fluid in the brain that affects more than one million Americans.
-
NICE Irreversible Electroporation for Treating Prostate Cancer Announcement
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute for Health and Care Excellence (NICE) Interventional Procedures Advisory Committee (IPAC) upgraded the guidance for...
-
Best HIFU ultrasound facelift machine for medical aesthetic
Today, the medical aesthetic industry has developed to make people more comfortable and safe in their pursuit of beauty. Among the many medical aesthetic procedures available, the best HIFU machine professional is a popular one. It is based on high intensity focused ultrasound technology and provides amazing aesthetic results. This article will reveal the magic of HIFU in a number of sections. Bvlaser is a ODM face lift HIFU machine manufacturer, we have HIFU vaginal tightening machine for sale. Principles of...
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related macular degeneration (nAMD) and phase II/III PHOTON trial in diabetic macular edema (DME) QUASAR is expected to enroll around 800 patients in 27 countries Study will add to the robust development program for aflibercept 8 mg, exploring the potential to achieve visual...
Customer comments
No comments were found for Aatru Medical Abstract Accepted for Presentation in Two Leading 2020 Wound Healing Conferences. Be the first to comment!